Treatment changes in prostatic hyperplasia and cancer, including androgen deprivation therapy and radiotherapy

被引:17
作者
Bostwick, DG
Ramnani, D
Cheng, L
机构
[1] Bostwick Labs, Richmond, VA 23226 USA
[2] Mayo Clin, Dept Pathol & Lab Med, Rochester, MN USA
[3] Indiana Univ, Indianapolis, IN 46204 USA
关键词
D O I
10.1016/S0094-0143(05)70195-6
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Treatment changes in the benign and cancerous prostate present great diagnostic challenges in pathologic interpretation. The urologist must provide the pertinent history of androgen deprivation or radiotherapy to assist the pathologist in understanding these changes to avoid misdiagnosis. This article describes the spectrum of treatment changes in the prostate resulting from hormonal therapy and radiotherapy, with an emphasis on the identification of adenocarcinoma and its mimics.
引用
收藏
页码:465 / +
页数:16
相关论文
共 146 条
[91]  
Mettlin CJ, 1997, CANCER, V80, P1261, DOI 10.1002/(SICI)1097-0142(19971001)80:7<1261::AID-CNCR10>3.3.CO
[92]  
2-L
[93]  
MILLS SE, 1986, CANCER, V57, P346, DOI 10.1002/1097-0142(19860115)57:2<346::AID-CNCR2820570226>3.0.CO
[94]  
2-E
[95]  
MOCELLINI AI, 1993, PROSTATE, V22, P291
[96]   Treatment of benign prostatic hyperplasia with 5-alpha-reductase inhibitor: Morphological changes in patients who fail to respond [J].
Montironi, R ;
Valli, M ;
Fabris, G .
JOURNAL OF CLINICAL PATHOLOGY, 1996, 49 (04) :324-328
[97]  
MONTIRONI R, 1995, PATHOL RES PRACT, V191, P873
[98]  
MONTIRONI R, 1994, J UROL PATHOL, V2, P161
[99]  
MONTIRONI R, IN PRESS EUR UROL
[100]  
Montironi R, 1996, J UROL PATHOL, V4, P123